Currently, molecular targeted therapies for prostate cancer undergoing clinical trials include therapies against prostate-specific membrane antigen (PSMA) [59] and prostate stem cell antigen (PSCA) [60], anti-angiogenesis drugs, and anti-tumor cell signaling COX-2 inhibitor drugs [61]. This evidence concerns the gene PSCA and prostate carcinoma.